A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02194491
- Locations
- 🇺🇸
Site US10001, New Haven, Connecticut, United States
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02175433
- Locations
- 🇺🇸
Site US0002, Stanford, California, United States
🇺🇸Site US0001, New York, New York, United States
🇺🇸Site US0004, Fairway, Kansas, United States
A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02171143
- Locations
- 🇺🇸
Metroplex Clinical Research Center, LLC, Dallas, Texas, United States
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸West Coast Clinical Trials, LLC, Costa Mesa, California, United States
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
- Conditions
- Interventions
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02150070
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02141425
- Locations
- 🇺🇸
California Clinical Trials Medical Group/Parexel, Glendale, California, United States
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 376
- Registration Number
- NCT02138747
- Locations
- 🇺🇸
Site US10010 Skyline Urology, Sherman Oaks, California, United States
🇨🇦Site CA15003 The Male/Female Health & Research Centre, Barrie, Ontario, Canada
🇺🇸Site US10035 Millennium Clinical Research Center, Arlington, Virginia, United States
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128321
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128893
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT02125435
- Locations
- 🇺🇸
PAREXEL International, Baltimore, Maryland, United States
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02113813
- Locations
- 🇺🇸
Site US10008, New York, New York, United States
🇺🇸Site US10010, Washington, District of Columbia, United States
🇺🇸Site US10006, Baltimore, Maryland, United States